Clinical trial
ACCLAIM - Advanced Chronic Heart Failure CLinical Assessment of Immune…
NCT00111969 · Vasogen, Industry · Completed
Key facts
| NCT number | NCT00111969 |
|---|---|
| Title | ACCLAIM - Advanced Chronic Heart Failure CLinical Assessment of Immune Modulation Therapy |
| Official title | A Multi-Center, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Assess the Effects of the Celacade™ System on Mortality and Morbidity in Patients With Chronic Heart Failure |
| Lead sponsor | Vasogen, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Heart Failure, Congestive |
| Intervention type | Device |
| Interventions | Celacade™ system |
| Enrollment | 2,016 |
| Start date | Jun 1, 2003 |
| Completion | Nov 1, 2005 |
| First posted | May 27, 2005 |
| Last update posted | Jul 4, 2006 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: